-

04:26:37 AM

FBIO Stock News

FBIO - Fortress Biotech Inc

08/11/22 4:30 PM

Nasdaq : FBIO

earnings

Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma presented at ASCO in June 2022; BLA submission expected YE 2022 MIAMI, Aug. 11, 2022 (GLOBE

RHEA-AI

neutral

08/11/22 8:00 AM

Nasdaq : FBIO

clinical trial

Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Triplex,

RHEA-AI

very positive

08/09/22 4:01 PM

Nasdaq : DERM, FBIO

earningslow float

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional sites underway in Europe open to enrollment Top-line data anticipated from the Phase 3 clinical program evaluating DFD-29 for the treatment of

RHEA-AI

neutral

08/03/22 8:00 AM

Nasdaq : DERM, FBIO

earningslow float

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses

RHEA-AI

neutral

07/22/22 8:00 AM

Nasdaq : FBIO

management

Fortress Biotech Appoints David Jin as Chief Financial Officer

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today

RHEA-AI

very positive

05/31/22 8:30 AM

Nasdaq : FBIO

clinical trial

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia Dotinurad was efficacious and

RHEA-AI

neutral

05/24/22 8:30 AM

Nasdaq : DERM, FBIO

low float

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological

RHEA-AI

neutral

05/23/22 8:30 AM

Nasdaq : DERM, FBIO

conferenceslow float

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today

RHEA-AI

neutral

05/18/22 8:30 AM

Nasdaq : FBIO

conferences

Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A.

RHEA-AI

neutral

05/12/22 4:01 PM

Nasdaq : FBIO

earnings

Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record Positive topline results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

FBIO Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.fortressbiotech.com
CeoLindsay Rosenwald
Security nameFortress Biotech Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees111
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2 Gansevoort St Fl 9
StateNew York
CityNew York
Zip10014-1667
CountryUS
Phone17816524500

About Fortress Biotech Inc

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high- potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital and Nationwide Children's Hospital.